The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-10 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Gelatin contains many functional groups like NH2, SH, and COOH which allow for gelatin to be modified using nanoparticles and biomolecules. Gelatin is an Extracellular Matrix protein which allows it to be applied for applications such as wound dressings, drug delivery and gene transfection. Starch: Starch is an inexpensive biodegradable biopolymer and copious in supply. Nanofibers and microfibers can be added to the polymer matrix to increase the mechanical properties of starch improving elasticity and strength. Without the fibers, starch has poor mechanical properties due to its sensitivity to moisture. Starch being biodegradable and renewable is used for many applications including plastics and pharmaceutical tablets. Cellulose: Cellulose is very structured with stacked chains that result in stability and strength. The strength and stability comes from the straighter shape of cellulose caused by glucose monomers joined by glycogen bonds. The straight shape allows the molecules to pack closely. Cellulose is very common in application due to its abundant supply, its biocompatibility, and is environmentally friendly. Cellulose is used vastly in the form of nano-fibrils called nano-cellulose. Nano-cellulose presented at low concentrations produces a transparent gel material. This material can be used for biodegradable, homogeneous, dense films that are very useful in the biomedical field. Alginate: Alginate is the most copious marine natural polymer derived from brown seaweed.
Technetium-99 produces the largest amount of LLFP radioactivity. It emits beta particles of low to medium energy but no gamma rays, so has little hazard on external exposure, but only if ingested. However, technetium's chemistry allows it to form anions (pertechnetate, TcO4−) that are relatively mobile in the environment. Tin-126 has a large decay energy (due to its following short half-life decay product) and is the only LLFP that emits energetic gamma radiation, which is an external exposure hazard. However, this isotope is produced in very small quantities in fission by thermal neutrons, so the energy per unit time from 126Sn is only about 5% as much as from 99Tc for U-235 fission, or 20% as much for 65% U-235+35% Pu-239. Fast fission may produce higher yields. Tin is an inert metal with little mobility in the environment, helping to limit health risks from its radiation. Selenium-79 is produced at low yields and emits only weak radiation. Its decay energy per unit time should be only about 0.2% that of Tc-99. Zirconium-93 is produced at a relatively high yield of about 6%, but its decay is 7.5 times slower than Tc-99, and its decay energy is only 30% as great; therefore its energy production is initially only 4% as great as Tc-99, though this fraction will increase as the Tc-99 decays. 93Zr does produce gamma radiation, but of a very low energy, and zirconium is relatively inert in the environment.
Initial strikes killed Iran's supreme leader Ali Khamenei and other top Iranian officials, and hundreds of Iranians were killed or injured. The Iranian Red Crescent said 24 provinces were affected. The strikes were coupled with cyberattacks on Iranian infrastructure, media, and phone apps, with messages calling on Iranians to rise up against their government. The cyberattacks resulted in a near-total internet blackout in Iran, lasting over 60 hours with connectivity dropping to as low as 1% of normal levels, disrupting government communications, state media, and public services. Iran restricted internet access, allowing access only to government-approved users until 26 May. On 28 February, Trump released a statement saying the purpose of the strikes was regime change, citing Iran's support for non-state actors such as Hamas and Hezbollah, killings of protesters, chants of "Death to America", and alleged history of attacking US civilians and soldiers, as well as the Iran hostage crisis. Trump and Benjamin Netanyahu warned of the potential threat of nuclear weapons in Iran and called on Iranians to overthrow their government. Israeli defense minister Israel Katz labeled the strikes a "pre-emptive attack" intended to "remove threats to...Israel". Iran denied that it intended to attack the US.
FC SKChF Sevastopol (reconstituted based on FC Sevastopol) FC TSK Simferopol (reconstituted based on SC Tavriya Simferopol) FC Zhemchuzhina Yalta (revived based on same club that was disqualified from Ukrainian competitions) The three clubs are from Crimea, a territory recognized by Ukraine and a majority of countries as part of Ukraine, but have been under effective Russian control as the Republic of Crimea since the annexation of Crimea by the Russian Federation. FC Sevastopol and SC Tavriya Simferopol last played in the 2013–14 Ukrainian Premier League, and were dissolved after the completion of the season. The three clubs were reformed as football organizations of the Russian Federation and joined the Russian Professional Football League starting from the 2014–15 season, after approval from the Russian Football Union. The inclusion of Crimean clubs in Russian competitions have not been approved by either FIFA or UEFA, and the Football Federation of Ukraine have lodged a complaint. On 22 August 2014, UEFA decided "that any football matches played by Crimean clubs organised under the auspices of the Russian Football Union will not be recognised by UEFA until further notice", and on 4 December 2014, decided to prohibit Crimean clubs to play in competitions organised by the Russian Football Union as from 1 January 2015 and for the region to be considered as a "special zone" for football purposes until further notice. In 2023 Crimean clubs began playing in the Russian system again, despite being a UEFA "special zone".
Sources: en.wikipedia.org
This term acquired a pejorative connotation in 18th-century Russia, and it currently means "petty bourgeois" or "narrow-minded philistine". The entire city of the late 17th century is contained within contemporary Moscow's Central Administrative Okrug. Numerous disasters befell the city during this period. Plague epidemics ravaged Moscow in 1570–1571, 1592, and 1654–1656. The plague killed more than 80% of the population in 1654–1655. Fires burned down much of the wooden city in 1626 and 1648. In 1712, Peter the Great moved his government to the newly built city of Saint Petersburg on the coast of the Baltic Sea.
=== Examples of bioactive antioxidant compounds === Physiological antioxidants are classified into two broad divisions, depending on whether they are soluble in water (hydrophilic) or in lipids (lipophilic). In general, water-soluble antioxidants react with oxidants in the cell cytosol and the blood plasma, while lipid-soluble antioxidants protect cell membranes from lipid peroxidation. These compounds may be synthesized in the body or obtained from the diet. The different antioxidants are present at a wide range of concentrations in body fluids and tissues, with some such as glutathione or ubiquinone mostly present within cells, while others such as uric acid are more systemically distributed (see table below). Some antioxidants are only found in a few organisms, and can be pathogens or virulence factors. The interactions between these different antioxidants may be synergistic and interdependent. The action of one antioxidant may therefore depend on the proper function of other members of the antioxidant system. The amount of protection provided by any one antioxidant will also depend on its concentration, its reactivity towards the particular ROS being considered, and the status of the antioxidants with which it interacts. Some compounds contribute to antioxidant defense by chelating transition metals and preventing them from catalyzing the production of free radicals in the cell. The sequesteration of iron by iron-binding proteins, such as transferrin and ferritin, is one such function.
==== MeSH E05.196.867 – spectrum analysis ==== MeSH E05.196.867.151 – circular dichroism MeSH E05.196.867.519 – magnetic resonance spectroscopy MeSH E05.196.867.519.274 – electron spin resonance spectroscopy MeSH E05.196.867.519.550 – nuclear magnetic resonance, biomolecular MeSH E05.196.867.576 – optical rotatory dispersion MeSH E05.196.867.660 – pulse radiolysis MeSH E05.196.867.726 – spectrometry, fluorescence MeSH E05.196.867.776 – spectrometry, gamma MeSH E05.196.867.776.751 – spectroscopy, mossbauer MeSH E05.196.867.800 – spectrometry, x-ray emission MeSH E05.196.867.800.360 – electron probe microanalysis MeSH E05.196.867.826 – spectrophotometry MeSH E05.196.867.826.300 – microspectrophotometry MeSH E05.196.867.826.551 – spectrophotometry, atomic MeSH E05.196.867.826.676 – spectrophotometry, infrared MeSH E05.196.867.826.676.700 – spectroscopy, fourier transform infrared MeSH E05.196.867.826.802 – spectrophotometry, ultraviolet MeSH E05.196.867.838 – spectroscopy, electron energy-loss MeSH E05.196.867.838.500 – microscopy, energy-filtering transmission electron MeSH E05.196.867.851 – spectroscopy, near-infrared MeSH E05.196.867.877 – spectrum analysis, mass MeSH E05.196.867.877.500 – mass fragmentography MeSH E05.196.867.877.600 – spectrometry, mass, electrospray ionization MeSH E05.196.867.877.750 – spectrometry, mass, fast atom bombardment MeSH E05.196.867.877.755 – spectrometry, mass, matrix-assisted laser desorption-ionization MeSH E05.196.867.877.760 – spectrometry, mass, secondary ion MeSH E05.196.867.890 – spectrum analysis, raman
=== Acquired resistance === Evolution of microbial resistance to vancomycin is a growing problem, especially in healthcare facilities such as hospitals. While newer alternatives to vancomycin exist, such as linezolid (2000) and daptomycin (2003), the widespread use of vancomycin makes resistance to it a significant worry, especially for individual patients if resistant infections are not quickly identified and the patient continues an ineffective treatment. Vancomycin-resistant Enterococcus emerged in 1986. Vancomycin resistance evolved in more common pathogenic organisms during the 1990s and 2000s, including vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA). Agricultural use of avoparcin, another similar glycopeptide antibiotic, may have contributed to the evolution of vancomycin-resistant organisms. One mechanism of resistance to vancomycin involves the alteration to the terminal amino acid residues of the NAM/NAG-peptide subunits, under normal conditions, D-alanyl-D-alanine, to which vancomycin binds. The D-alanyl-D-lactate variation results in the loss of one hydrogen-bonding interaction (4, as opposed to 5 for D-alanyl-D-alanine) possible between vancomycin and the peptide. This loss of just one point of interaction results in a 1000-fold decrease in affinity. The D-alanyl-D-serine variation causes a six-fold loss of affinity between vancomycin and the peptide, likely due to steric hindrance. In enterococci, this modification appears to be due to the expression of an enzyme that alters the terminal residue.
=== Future development of structure activity relationship === The application of an aryloxypropanamine scaffold has generated a number of potent MAOIs. Before the development of duloxetine, the exploration of aryloxypropanamine structure activity relationships resulted in the identification of fluoxetine and atomoxetine. The same motif can be found in reboxetine where it is constrained in a morpholine ring system. Some studies have been made where the oxygen in reboxetine is replaced by sulfur to give arylthiomethyl morpholine. Some of the arylthiomethyl morpholine derivatives maintain potent levels of serotonin and norepinephrine reuptake inhibition. Dual serotonin and norepinephrine reuptake inhibition resides in different enantiomers for arylthiomethyl morpholine scaffold. Possible drug candidates with dual serotonin and norepinephrine reuptake inhibitory activity have also been derived from piperazine, 3-amino-pyrrolidine and benzylamine templates.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.